|
|
||||||||
B Regulates VCAM-1 Expression on Fibroblast-Like Synoviocytes1



*
Department of Microbiology and Immunology,
Immunology/Rheumatology Unit, Department of Medicine, and
Department of Orthopaedics, University of Rochester Medical Center, Rochester, NY 14642
Expression of VCAM-1 on synovial fibroblasts is a clinical hallmark
of rheumatoid arthritis. The interaction of VCAM-1 and its integrin
receptor very late Ag-4 is believed to be critically involved in the
recruitment and retention of immune cells in the inflamed joints. To
study the regulation of VCAM-1 in synovial fibroblasts, fibroblast-like
synoviocytes (FLS) were isolated from the knee joints of normal mice
and passaged repeatedly to obtain a homogeneous cell population. We
have found that VCAM-1 is constitutively expressed on mouse FLS (mFLS)
and that its surface expression is further increased after exposure to
TNF-
. Nuclear translocation of transcription factor NF-
B
including P50/P50 homodimer and P65/P50 heterodimer was activated by
TNF-
treatment. In mFLS stably expressing a dominant-negative mutant
of the inhibitory protein I-
B
- (mI-
B), which does not undergo
proteolytic degradation, NF-
B remains in the cytosol and its
activation in response to TNF-
is abolished. VCAM-1 protein
expression after TNF-
stimulation was blocked in cells expressing
the mI-
B. This effect is likely due to the loss of NF-
B-mediated
transcription of VCAM-1, because the 5-fold increase in mRNA levels in
response to TNF-
is absent in the mutant cells. To confirm these
findings, we transduced mFLS with an adenoviral vector containing the
mI-
B transgene. VCAM-1 expression was also blocked by mI-
B in
this system, whereas cells transduced with a control adenoviral vector
remained responsive to TNF-
. These results indicate that NF-
B
mediates TNF-
-induced VCAM-1 expression on
mFLS.
This article has been cited by other articles:
![]() |
A. Huang, Y.-Y. Zhang, K. Chen, K. Hatakeyama, and J. F. Keaney Jr Cytokine-Stimulated GTP Cyclohydrolase I Expression in Endothelial Cells Requires Coordinated Activation of Nuclear Factor-{kappa}B and Stat1/Stat3 Circ. Res., February 4, 2005; 96(2): 164 - 171. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ulrich-Vinther, E. E. Carmody, J. J. Goater, K. Søballe, R. J. O'Keefe, and E. M. Schwarz Recombinant Adeno-Associated Virus-Mediated Osteoprotegerin Gene Therapy Inhibits Wear Debris-Induced Osteolysis J. Bone Joint Surg. Am., August 12, 2002; 84(8): 1405 - 1412. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hideshima, D. Chauhan, P. Richardson, C. Mitsiades, N. Mitsiades, T. Hayashi, N. Munshi, L. Dang, A. Castro, V. Palombella, et al. NF-kappa B as a Therapeutic Target in Multiple Myeloma J. Biol. Chem., May 3, 2002; 277(19): 16639 - 16647. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. M. Morel, C. C. Park, J. M. Woods, and A. E. Koch A Novel Role for Interleukin-18 in Adhesion Molecule Induction through NFkappa B and Phosphatidylinositol (PI) 3-Kinase-dependent Signal Transduction Pathways J. Biol. Chem., September 28, 2001; 276(40): 37069 - 37075. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |